Sarepta Therapeutics (LTS:0L35) Margin of Safety % (DCF Dividends Based) : N/A (As of May. 01, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Sarepta Therapeutics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

As of today (2024-05-01), Sarepta Therapeutics's Predictability Rank is 2-Stars. Sarepta Therapeutics's intrinsic value calculated from the Discounted Dividend model is $-24.07 and current share price is $128.6574. Consequently,

Sarepta Therapeutics's Margin of Safety % (DCF Dividends Based) using Discounted Dividend model is N/A.

Competitive Comparison of Sarepta Therapeutics's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Sarepta Therapeutics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sarepta Therapeutics's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Margin of Safety % (DCF Dividends Based) falls into.

Sarepta Therapeutics Margin of Safety % (DCF Dividends Based) Calculation

Sarepta Therapeutics's Margin of Safety % (DCF Dividends Based) for today is calculated as

Margin of Safety % (DCF Dividends Based)	=	(Intrinsic Value: DCF (Dividends Based)	-	Current Price)	/	Intrinsic Value: DCF (Dividends Based)
	=	(0.00	-	128.6574)	/	0.00
	=	N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Dividend model with default parameters.

Sarepta Therapeutics Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sarepta Therapeutics (LTS:0L35) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (LTS:0L35) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

SRPT:USA AB3A:Germany S1RP34:Brazil

Address

215 First Street, Suite 415, Cambridge, MA, USA, 02142

Website

https://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics (LTS:0L35) Headlines

No Headlines